文献速递糖尿病

评估西格列汀在老年参与者中的安全性:来自西格列汀心血管结局评估试验(TECOS)的分析

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
PubMed 文献 · Diabetes Care · 2017-01-05

TECOS试验是一项随机双盲安慰剂对照研究,评估西格列汀对2型糖尿病合并心血管疾病患者主要复合心血管结局的影响。本文分析≥75岁参与者的基线特征与临床结局,发现老年患者主要结局、死亡、严重低血糖和骨折发生率更高,但西格列汀对心血管风险无显著影响,未提出新的安全性问题。

要点

  • ≥75岁参与者占14%,主要结局发生率6.46 vs 3.67事件/100人年,风险比1.72。
  • 老年队列中,西格列汀对主要复合结局无显著影响(HR 1.10,95%CI 0.89-1.36)。
  • 西格列汀未显著增加死亡、心衰住院、严重低血糖、急性胰腺炎或胰腺癌风险。

核心结论

  • 在血糖控制良好且合并心血管疾病的老年2型糖尿病患者中,西格列汀对心血管风险呈中性效应,未提出显著安全性问题。

研究设计与样本

  • TECOS为随机、双盲、安慰剂对照试验,纳入2型糖尿病(HbA1c≥6.5%且≤8.0%)合并心血管疾病患者,本文分析其中年龄≥75岁的参与者。
  • 共14,351例记录年龄的参与者中,2,004例(14%)年龄≥75岁,平均年龄78.3岁(SD 3.1),男性占68%,2型糖尿病病程中位数12.0年(IQR 7,21)。

主要发现

  • 中位随访2.9年期间,老年参与者主要结局发生率为6.46 vs 3.67事件/100人年(风险比1.72,95%CI 1.52-1.94),死亡风险比2.52(95%CI 2.20-2.89),严重低血糖风险比1.53(95%CI 1.15-2.03),骨折风险比1.84(95%CI 1.44-2.35)。
  • 老年队列中,西格列汀对主要复合结局无显著影响(HR 1.10,95%CI 0.89-1.36),对死亡(HR 1.05,95%CI 0.83-1.32)、心力衰竭住院(HR 0.99,95%CI 0.65-1.49)、严重低血糖(HR 1.03,95%CI 0.62-1.71)、急性胰腺炎和胰腺癌发生率及严重不良事件均无显著影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin on a primary composite outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or unstable angina hospitalizations in patients with type 2 diabetes (HbA1c ≥6.5% [48 mmol/mol] and ≤8.0% [64 mmol/mol]) and cardiovascular disease. We analyzed baseline characteristics and clinical outcomes for TECOS participants aged ≥75 years. RESEARCH DESIGN AND METHODS: Clinical and safety event summaries are presented for older versus younger participants and for the treatment groups within the older cohort. RESULTS: Of 14,351 participants with age recorded, 2,004 (14%) were ≥75 years old (mean age 78.3 years [SD 3.1]), with 68% men and type 2 diabetes duration median 12.0 years (IQR 7, 21). During 2.9 years median follow-up, older participants had higher rates of the primary outcome (6.46 vs. 3.67 events per 100 person-years; hazard ratio 1.72 [95% CI 1.52-1.94]), death (2.52 [2.20-2.89]), severe hypoglycemia (1.53 [1.15-2.03]), and fractures (1.84 [1.44-2.35]). In the older cohort, sitagliptin did not significantly impact the primary composite (1.10 [0.89-1.36]), death (1.05 [0.83-1.32]), heart failure hospitalization (0.99 [0.65-1.49]), severe hypoglycemia (1.03 [0.62-1.71]), rates of acute pancreatitis and pancreatic cancer, or serious adverse events. CONCLUSIONS: Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bethel MA, Engel SS, Green JB, et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 2017. PMID: 28057693. doi:10.2337/dc16-1135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。